Department of Pathology, University of California San Francisco.
Cancer Risk Program, Hellen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
Am J Surg Pathol. 2019 Sep;43(9):1170-1179. doi: 10.1097/PAS.0000000000001293.
Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC), caused by a germline mutation in the fumarate hydratase (FH) gene, predisposes patients to uterine and cutaneous smooth muscle tumors and an aggressive type of renal cell carcinoma. Almost all women with HLRCC develop symptomatic uterine leiomyomas resulting in surgery at young ages, presenting an ideal opportunity for early detection of these patients and the implementation of surveillance measures for renal cell carcinoma. FH-deficient uterine leiomyomas can show characteristic morphologic features (FH-d morphology) that have been previously described. Immunohistochemistry (IHC) for FH can also be helpful in detecting FH deficiency in leiomyomas, which manifests as complete loss of staining for FH. However, the distribution and topography of FH-d morphology and FH loss by IHC in the context of multiple leiomyomas in patients with HLRCC has not been evaluated. The aim of this study is to describe in detail the clinical and pathologic characteristics of uterine leiomyomas from women with HLRCC. Six patients with proven FH germline mutations were included. All available slides were reviewed and FH IHC staining was performed on multiple blocks when possible. Clinical data were extracted from online medical records. All 6 patients presented with symptomatic uterine fibroids and underwent myomectomy (age 24 to 36 y), followed by hysterectomy in 2 patients (age 31 and 40 y). Specimens showed conventional leiomyomas, cellular leiomyomas and leiomyomas with bizarre nuclei. FH-d morphology was present in leiomyomas from all patients and was typically observed as a diffuse finding in the majority of slides across different leiomyoma types. FH-d morphology was absent in some leiomyoma sections from one patient and the morphologic features were focal and subtle in leiomyomas from 2 patients. Both hysterectomy specimens were also notable for showing scattered irregular tongues and nodules of smooth muscle proliferation (leiomyomatosis-like) in the background myometrium. Immunohistochemical staining of multiple slides per patient for FH showed either retained staining in all sections (2/6 cases), loss of staining in all sections (1 case) or variable staining across different leiomyomas (3 cases). In conclusion, patients with HLRCC undergo surgery at young ages for highly symptomatic uterine leiomyomas. FH-d morphology is usually a diffuse and well developed finding across different leiomyomas but may be absent or focal and subtle. FH IHC can show variable results and presence of retained FH staining should not be used to exclude the possibility of HLRCC. Referral for genetic counselling and testing should be considered in a young patient with uterine leiomyomas showing FH-d morphology even if immunohistochemical staining for FH is retained.
遗传性平滑肌瘤病和肾细胞癌综合征(HLRCC)是由富马酸水合酶(FH)基因突变引起的,使患者易患子宫和皮肤平滑肌肿瘤以及侵袭性肾细胞癌。几乎所有患有 HLRCC 的女性都会因子宫平滑肌瘤出现症状而接受手术,这为这些患者的早期发现和肾细胞癌的监测措施提供了理想的机会。FH 缺陷型子宫平滑肌瘤可能表现出先前描述的特征性形态特征(FH-d 形态)。FH 免疫组化(IHC)也可有助于检测 FH 缺陷型平滑肌瘤,其表现为 FH 完全缺失染色。然而,在 HLRCC 患者的多个平滑肌瘤中,FH-d 形态和 FH 缺失的分布和分布尚未得到评估。本研究的目的是详细描述 HLRCC 患者子宫平滑肌瘤的临床和病理特征。纳入了 6 名经证实存在 FH 种系突变的患者。对所有可用的切片进行了回顾,并尽可能在多个切片上进行 FH IHC 染色。从在线病历中提取临床数据。所有 6 名患者均因有症状的子宫肌瘤就诊并接受了肌瘤切除术(年龄 24 至 36 岁),随后 2 名患者(年龄 31 岁和 40 岁)接受了子宫切除术。标本显示为常规平滑肌瘤、细胞性平滑肌瘤和具有奇异核的平滑肌瘤。FH-d 形态存在于所有患者的平滑肌瘤中,在不同平滑肌瘤类型的大多数切片中通常表现为弥漫性发现。一名患者的一些平滑肌瘤切片中不存在 FH-d 形态,两名患者的平滑肌瘤形态特征为局灶性和细微。两名患者的平滑肌瘤中也可见散在的不规则舌状和结节状平滑肌增生(平滑肌瘤样)。对每位患者的多个切片进行 FH 的免疫组化染色显示,2/6 例所有切片均保留染色,1 例所有切片均缺失染色,3 例不同平滑肌瘤的染色不同。总之,HLRCC 患者因高度有症状的子宫平滑肌瘤而在年轻时接受手术。FH-d 形态通常是不同平滑肌瘤中弥漫且发育良好的发现,但可能不存在或局灶性和细微。FH IHC 可能会产生不同的结果,保留的 FH 染色不应被用来排除 HLRCC 的可能性。即使 FH 免疫组化染色保留,对于表现出 FH-d 形态的年轻患者,也应考虑进行遗传咨询和检测。